Skip to main content
SpringerLink
Log in

Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia

Considerations in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Although the majority of patients with chronic lymphocytic leukaemia (CLL) are of advanced age, these patients have not been well represented in past clinical trials. This has resulted in a lack of evidence that has complicated treatment in this patient group. However, data from an increasing number of subgroup analyses of recent trials as well as from trials specifically designed for elderly patients with CLL have provided some insight into the feasibility of the available treatments, thus allowing development of the first evidence-based recommendations for the pharmacotherapeutic management of these patients. Physically fit patients without significant co-morbidity are likely to benefit from the standard treatment of fludarabine, cyclophosphamide and rituximab (FCR). However, whether treatment with purine analogues and/or CD20 antibodies is also beneficial in physically unfit patients suffering from additional health problems remains to be determined. Latest data suggest that the alkylating drug chlorambucil rather than fludarabine is a reasonable chemotherapeutic backbone for chemoimmunotherapy in these patients. Trials are now underway to investigate combinations of chlorambucil with rituximab or with novel CD20 antibodies (GA101 [afutuzumab], ofatumumab) in older CLL patients. In parallel, other regimens, including bendamustine or lenalidomide with or without the addition of rituximab, low-dose fludarabine and low-dose FCR, hold promise in elderly patients with previously untreated or relapsed CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Foon KA, Hallek MJ. Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia 2010 Mar; 24(3): 500–11

    Article  PubMed  CAS  Google Scholar 

  2. Lin TS. New agents in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2010 Jan; 5(1): 29–34

    Article  PubMed  Google Scholar 

  3. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996 May 25; 347(9013): 1432–8

    PubMed  CAS  Google Scholar 

  4. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001 Oct 15; 98(8): 2319–25

    Article  PubMed  CAS  Google Scholar 

  5. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000 Dec 14; 343(24): 1750–7

    Article  PubMed  CAS  Google Scholar 

  6. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006 Feb 1; 107(3): 885–91

    Article  PubMed  CAS  Google Scholar 

  7. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007 Jul 21; 370(9583): 230–9

    Article  PubMed  CAS  Google Scholar 

  8. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007 Mar 1; 25(7): 793–8

    Article  PubMed  CAS  Google Scholar 

  9. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 Sep 10; 27(26): 4378–84

    Article  PubMed  CAS  Google Scholar 

  10. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007 Dec 10; 25(35): 5616–23

    Article  PubMed  CAS  Google Scholar 

  11. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [abstract no. 535]. Blood 2009; 114(22)

    Google Scholar 

  12. Altekruse SF, Kosary CL, Krpacho M, et al. SEER stat fact sheets: chronic lymphocytic leukemia. SEER cancer statistics review, 1975–2007. Bethesda (MD): National Cancer Institute [online]. Available from URL: http://seer.cancer.gov/statfacts/html/clyl.html [Accessed 2010 Aug 1]

  13. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009 Oct 15; 114(16): 3382–91

    Article  PubMed  CAS  Google Scholar 

  14. Hillmen P, Gribben JG, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL) [abstract no. 3428]. Blood 2009; 114(22)

    Google Scholar 

  15. Ferrajoli A, O’Brien S, Wierda W, et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL) [abstract no. 45]. Blood 2008; 112(11)

    Google Scholar 

  16. Ferrajoli A, O’Brien S, Wierda W, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients [abstract no. 87]. Leuk Lymphoma 2005; 46(Suppl. 1)

    Google Scholar 

  17. Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic leukaemia. Hematol Oncol 2008 Dec; 26(4): 247–51

    Article  PubMed  CAS  Google Scholar 

  18. Bezares RF, Murro HH, Celebrin L, et al. Fludarabine (F) administered on a three (F3a) alternate day-basis in selected CLL patients [abstract no. 53]. Leuk Lymphoma 2001; 42(Suppl. 1)

    Google Scholar 

  19. Marotta G, Bigazzi C, Lenoci M, et al. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000 Dec; 85(12): 1268–70

    PubMed  CAS  Google Scholar 

  20. Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003 Nov; 44(11): 1947–50

    Article  PubMed  CAS  Google Scholar 

  21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun 15; 111(12): 5446–56

    Article  PubMed  CAS  Google Scholar 

  22. Shanafelt TD, Rabe KG, Kay NE, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer 2010 Oct 15; 116(20): 4777–87

    Article  PubMed  Google Scholar 

  23. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 2006 Jul; 13(4): 266–72

    PubMed  Google Scholar 

  24. Josefsson P, Geisler CH, Leffers H, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007 Jun 1; 109(11): 4973–9

    Article  PubMed  CAS  Google Scholar 

  25. Cramer P, Goede V, Jenke P, et al. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III-trials of the German CLL Study Group [abstract no. 2840]. Blood 2006; 108(11)

    Google Scholar 

  26. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups [abstract no. 2367]. Blood 2009; 114(22)

    Google Scholar 

  27. Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract no. 325]. Blood 2008; 112(11)

    Google Scholar 

  28. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15; 109(2): 405–11

    Article  PubMed  CAS  Google Scholar 

  29. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009 Mar 20; 27(9): 1492–501

    Article  PubMed  CAS  Google Scholar 

  30. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005 Oct; 90(10): 1357–64

    PubMed  CAS  Google Scholar 

  31. Koppler H, Heymanns J, Pandorf A, et al. Bendamustine plus mitoxantrone: a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 2004 May; 45(5): 911–3

    Article  PubMed  Google Scholar 

  32. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008 Jan; 49(1): 49–56

    Article  PubMed  Google Scholar 

  33. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989 Jul; 74(1): 19–25

    PubMed  CAS  Google Scholar 

  34. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996 Jul; 14(7): 2160–6

    PubMed  CAS  Google Scholar 

  35. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 1989 Apr; 7(4): 433–8

    PubMed  CAS  Google Scholar 

  36. Robertson LE, O’Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995 Sep; 9(9): 1444–9

    PubMed  CAS  Google Scholar 

  37. German CLL Study Group. Fludarabine and darbepoetin alfa in treating older patients with chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT00281892]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  38. O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001 Apr 15; 19(8): 2165–70

    PubMed  Google Scholar 

  39. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009 Oct; 23(10): 1779–89

    Article  PubMed  CAS  Google Scholar 

  40. Tam CS, O’Brien S, Wierda W, et al. Long term results of the fludarabine, cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008 Aug 15; 112(4): 975–80

    Article  PubMed  CAS  Google Scholar 

  41. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010 Apr 1; 28(10): 1756–65

    Article  PubMed  CAS  Google Scholar 

  42. Lamanna N, Weiss MA. Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia. Curr Oncol Rep 2007 Sep; 9(5): 335–6

    Article  PubMed  Google Scholar 

  43. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006 Apr 1; 24(10): 1575–81

    Article  PubMed  CAS  Google Scholar 

  44. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 205]. Blood 2009; 114(22)

    Google Scholar 

  45. Fischer K, Stilgenbauer S, Schweighofer C, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 320]. Blood 2008; 112(11)

    Google Scholar 

  46. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 Feb 1; 27(4): 498–503

    Article  PubMed  CAS  Google Scholar 

  47. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010 Jun; 51(6): 983–94

    Article  PubMed  CAS  Google Scholar 

  48. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010 Apr 1; 28(10): 1749–55

    Article  PubMed  CAS  Google Scholar 

  49. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia [abstract no. 884]. Blood 2009; 114(22)

    Google Scholar 

  50. Hoffmann-La Roche. CLL11: a study of RO5072759 with chlorambucil in patients with previously untreated chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT01010061]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  51. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 May 15; 99(10): 3554–61

    Article  PubMed  CAS  Google Scholar 

  52. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005 Oct 1; 23(28): 7024–31

    Article  PubMed  CAS  Google Scholar 

  53. Engert A, Gercheva L, Robak T, et al. Improved progression-free survival (PFS) of alemtuzumab (Campath®, MabCampath®) plus fludarabine (Fludara®) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial [abstract no. 537]. Blood 2009; 114(22)

    Google Scholar 

  54. Wierda WG, Obrien S, Ferrajoli A, et al. Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL [abstract no. 719]. Blood 2005; 106(11)

    Google Scholar 

  55. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002 Aug 8; 347(6): 452–3

    Article  PubMed  Google Scholar 

  56. Cortelezzi A, Pasquini MC, Gardellini A, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009 Nov; 23(11): 2027–33

    Article  PubMed  CAS  Google Scholar 

  57. Elter T, James R, Stilgenbauer S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group [abstract no. 209]. Blood 2009; 114(22)

    Google Scholar 

  58. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008 Jun 1; 111(11): 5291–7

    Article  PubMed  CAS  Google Scholar 

  59. Ferrajoli A, Badoux XC, O’Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) [abstract no. 206]. Blood 2009; 114(22)

    Google Scholar 

  60. Lin TS. Lenalidomide: what is the right dose in CLL? [letter]. Blood 2008 Jun 1; 111(11): 5268

    Article  PubMed  CAS  Google Scholar 

  61. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007 Jan; 21(1): 12–7

    Article  PubMed  CAS  Google Scholar 

  62. Caballero D, Garcia-Marco JA, Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005 Nov 1; 11(21): 7757–63

    Article  PubMed  CAS  Google Scholar 

  63. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005 May 20; 23(15): 3433–8

    Article  PubMed  Google Scholar 

  64. Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol 2005 Aug 20; 23(24): 5788–94

    Article  PubMed  Google Scholar 

  65. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000 Apr; 25(7): 717–22

    Article  PubMed  CAS  Google Scholar 

  66. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009: 602–9

    Google Scholar 

  67. Toze CL, Sangara RN, Connors JM, et al. Impact of comorbidity index on outcome with allogeneic hematopoetic stem cell transplantation for chronic lymphocytic leukemia [abstract no. 3305]. Blood 2008; 112(11)

    Google Scholar 

  68. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5(3): 224–37

    Article  PubMed  CAS  Google Scholar 

  69. Reynolds C, Di Bella N, Lyons RM, et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia [abstract no. 327]. Blood 2008; 112(11)

    Google Scholar 

  70. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009 Jul 1; 115(13): 2824–36

    Article  PubMed  CAS  Google Scholar 

  71. Montserrat E, Moreno C, Esteve J, et al. How I treat refractory CLL. Blood 2006 Feb 15; 107(4): 1276–83

    Article  PubMed  CAS  Google Scholar 

  72. Zenz T, Mohr J, Edelmann J, et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009 Mar; 50(3): 510–3

    Article  PubMed  CAS  Google Scholar 

  73. GlaxoSmithKline. Ofatumumab + chlorambucil vs. chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia (COMPLEMENT 1) [ClinicalTrials.gov Identifier NCT00748189]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  74. Celgene Corporation. Study of the effectiveness & safety of lenalidomide versus chlorambucil as first line therapy for elderly patients with B-cell CLL (the ORIGIN trial) [ClinicalTrials.gov Identifier NCT00910910]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  75. Centre Hospitalier Universitaire Bretonneau de Tours. Fludarabine, cyclophosphamide, and rituximab followed by rituximab or observation in treating older patients with previously untreated B-cell chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT00645606]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 10]

  76. Hoffmann-La Roche. A study of MabThera added to bendamustine or chlorambucil in patients with chronic lymphocytic leukemia (MaBLe) [ClinicalTrials.gov Identifier NCT01056510]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  77. Hoffmann-La Roche. A study of MabThera (rituximab) plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT00738374]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  78. Chronic Lymphocytic Leukemia Research Consortium. Multi-center trial of Revlimid® and rituximab, for first-line treatment of chronic lymphocytic leukemia (CLL) [ClinicalTrials.gov Identifier NCT00628238]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  79. University of Kentucky. Frontline treatment with bendamustine in combination with rituximab in adults age 65 or older with chronic lymphocytic leukemia (CLL) [ClinicalTrials.gov Identifier NCT00758693]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  80. Sarah Cannon Research Institute. Ofatumumab for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma [ClinicalTrials.gov Identifier NCT01113632]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

  81. Memorial Sloan-Kettering Cancer Center. Lenalidomide in patients with chronic lymphocytic leukemia older than 65 years of age [ClinicalTrials.gov Identifier NCT01011894]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Valentin Goede has received honoraria from Roche, Amgen and Bayer. Michael Hallek has received speakers’ honoraria and research grants from Roche and Mundipharma.

Author information

Authors and Affiliations

  1. German CLL Study Group, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany

    Valentin Goede & Michael Hallek

Authors
  1. Valentin Goede
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valentin Goede.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goede, V., Hallek, M. Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia. Drugs Aging 28, 163–176 (2011). https://doi.org/10.2165/11587650-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11587650-000000000-00000

Keywords

Search

Navigation